Charité - Campus Benjamin Franklin

Berlin 12203

4 studies enrolling now · 29 studies all time

What they study most

Acute Coronary Syndrome, Acute Myeloid Leukemia, Alzheimer's Disease, Amyloidosis, Anaplastic Large-Cell Lymphoma, Anemia, Angina, Stable, Angina, Unstable, Anticoagulants, Aspergillosis, Atherosclerotic Cardiovascular Disease, Atrial Fibrillation

Studies at this site

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms — Recruiting now
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions — Recruiting now
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) — Recruiting now
CHAMPION-AF Clinical Trial — Running, not enrolling
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis — Running, not enrolling
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment — Running, not enrolling
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma — Completed
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer — Completed
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis — Completed
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi — Completed
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus — Stopped early
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease — Stopped early
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas — Completed
Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy — Status unconfirmed
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) — Completed
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) — Completed
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy — Stopped early
The Safety And Efficacy Of Maintenance Therapy With CP-690,550 — Completed
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients — Completed
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy — Completed
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer — Stopped early
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study — Status unconfirmed